MRSN - Mersana Therapeutics, Inc.

QQQ $ 480.15 $ -1.01 (-0.21 %)

DIA $ 408.54 $ -0.55 (-0.13 %)

SPY $ 558.65 $ -0.91 (-0.16 %)

TLT $ 98.68 $ 0.78 (0.8 %)

GLD $ 232.46 $ 0.85 (0.37 %)

Previous Close

$ 1.31

Open

$ 1.37

Bid

$ 1.29 x 500

Ask

$ 1.31 x 1,000

Day's Range

$ 1.27 - $ 1.38

52 Week Range

$ 1.07 - $ 6.28

Volume

684,403

Average Volume

Market Cap

160.4M

Beta (5Y Monthly)

$ 2.08

PE Ratio (TTM)

EPS (TTM)

TBD

Earnings Date

Dividend & Yield

na ($ 0.00)

Last Ex-Dividend

1y Target Est

TBD na

How to Read 10-K & 10-Q Reports To View SEC Filing Reports, Please Register or Sign In

#	Filing Date	Period End Date	Type
1	08-13-2024	06-30-2024	10-Q
2	05-09-2024	03-31-2024	10-Q
3	02-28-2024	12-31-2023	10-K
4	11-07-2023	09-30-2023	10-Q
5	08-08-2023	06-30-2023	10-Q
6	05-09-2023	03-31-2023	10-Q
7	02-28-2023	12-31-2022	10-K
8	11-07-2022	09-30-2022	10-Q
9	08-08-2022	06-30-2022	10-Q
10	05-09-2022	03-31-2022	10-Q
11	02-28-2022	12-31-2021	10-K
12	11-09-2021	09-30-2021	10-Q
13	08-06-2021	06-30-2021	10-Q
14	05-10-2021	03-31-2021	10-Q
15	02-26-2021	12-31-2020	10-K
16	11-09-2020	09-30-2020	10-Q
17	08-07-2020	06-30-2020	10-Q
18	05-08-2020	03-31-2020	10-Q
19	02-28-2020	12-31-2019	10-K
20	11-06-2019	09-30-2019	10-Q
21	08-08-2019	06-30-2019	10-Q
22	05-09-2019	03-31-2019	10-Q
23	03-08-2019	12-31-2018	10-K
24	11-13-2018	09-30-2018	10-Q
25	08-14-2018	06-30-2018	10-Q
26	05-15-2018	03-31-2018	10-Q
27	03-28-2018	12-31-2017	10-K
28	11-13-2017	09-30-2017	10-Q
29	08-11-2017	06-30-2017	10-Q

Guide for Analyst Ratings To View Analyst Ratings, Please Register or Sign In

#	Date	Analyst Firm	Upside/Downside	Price Target Change	Rating Change	Current Rating

News
OPINIONS

News

OPINIONS

Baird Maintains Neutral on Mersana Therape...
08/14/2024 11:41:18

Baird analyst Colleen Kusy maintains Mersana Therapeutics (NASDAQ:MRSN) with a Neutral and lowers the price target from $4 t...

Mersana Therapeutics Continues To Expect C...
08/13/2024 11:03:49

Mersana Therapeutics Q2 2024 GAAP EPS $(0....
08/13/2024 11:03:13

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.20) per share which missed the analyst consensus estimate o...

Mersana Therapeutics Continues To Expect C...
05/09/2024 11:11:55

Mersana Therapeutics Q1 2024 GAAP EPS $(0....
05/09/2024 11:11:07

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which beat the analyst consensus estimate of ...

why-teledyne-technologies-shares-are-trading-lower-by-9-here-are-other-stocks-moving-in-wednesdays-mid-day-session

Why Teledyne Technologies Shares Are Tradi...
04/24/2024 17:57:43

The Analyst Verdict: Mersana Therapeutics ...
03/19/2024 13:00:37

JP Morgan Upgrades Mersana Therapeutics to...
03/19/2024 09:50:17

JP Morgan analyst Brian Cheng upgrades Mersana Therapeutics (NASDAQ:MRSN) from Underweight to Neutral and announces $5 price...

12-health-care-stocks-moving-in-fridays-after-market-session

12 Health Care Stocks Moving In Friday's A...
03/15/2024 21:33:52

why-butterfly-network-shares-are-trading-lower-by-22-here-are-other-stocks-moving-in-thursdays-mid-day-session

Why Butterfly Network Shares Are Trading L...
02/29/2024 19:00:01

Shares of Butterfly Network, Inc. (NASDAQ: BFLY) fell sharply during Thursday’s session after the company reported mixed four...

Hormel Foods Reports Upbeat Earnings, Join...
02/29/2024 16:30:35

U.S. stocks were higher, with the Nasdaq Composite gaining around 50 points on Thursday.

Expert Outlook: Mersana Therapeutics Throu...
02/29/2024 16:00:51

Wedbush Upgrades Mersana Therapeutics to O...
02/29/2024 15:51:48

Wedbush analyst David Nierengarten upgrades Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Outperform and raises the pri...

Truist Securities Upgrades Mersana Therape...
02/29/2024 14:03:40

Truist Securities analyst Asthika Goonewardene upgrades Mersana Therapeutics (NASDAQ:MRSN) from Hold to Buy and maintains th...

Baird Maintains Neutral on Mersana Therape...
02/29/2024 12:17:32

Baird analyst Colleen Kusy maintains Mersana Therapeutics (NASDAQ:MRSN) with a Neutral and raises the price target from $1 t...

Guggenheim Upgrades Mersana Therapeutics t...
02/29/2024 10:57:32

Guggenheim analyst Michael Schmidt upgrades Mersana Therapeutics (NASDAQ:MRSN) from Neutral to Buy and announces $7 price ta...

Mersana Therapeutics Continues To Expect C...
02/28/2024 12:09:34

Mersana Therapeutics Q4 EPS $(0.16), Inlin...
02/28/2024 12:02:25

Mersana Therapeutics (NASDAQ:MRSN) reported quarterly losses of $(0.16) per share which met the analyst consensus estimate. Thi...

Earnings Scheduled For February 28, 2024
02/28/2024 11:24:02

Companies Reporting Before The Bell • ICL Group (NYSE:ICL) is likely to report quarterly earnings at $0.08 per share on revenu...

A Preview Of Mersana Therapeutics's Earnings
02/27/2024 19:01:37